Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:

Broadly neutralizing antibodies (bNabs) are thought to be key in the development of protective vaccines and cure of HIV infection. Over recent years, a lot of progress has been made in better understanding elicitation, isolation, mode of activity, and binding of bNabs. In addition, it has been recognized that a part of neutralization, effector functions can be of interest in the development of cure strategies and that several isolated bNabs do have the potential to also play a role for Antiretroviral therapy (ART) and Pre-exposure prophylaxis (PrEP). This session will provide state-of-the-art knowledge on elicitation of bNabs in natural HIV-1 infection, vaccine development, potential use in treatment, and cure of HIV-1.

11:00
THSY0401
Introduction
11:05
THSY0402
Factors determining bNab elicitation in HIV-infected individuals during natural infection: Challenges a vaccine has to overcome
Alexandra Trkola, University of Zurique, Switzerland
11:20
THSY0403
Maturation of bNabs in HIV-1 infected patients (specifics of B-cell maturation), what is different from other infections?
Michel Nussenzweig, The Rockefeller University, United States
11:35
THSY0404
Induction of bNabs by vaccines: where do we stand, what is being needed for success
Rogier Sanders, AMC, Netherlands
Slides
11:50
THSY0405
bNabs for clinical use: antiviral activity and effector functions other than neutralization
Lynn Morris, University of the Witwatersrand, South Africa
12:05
THSY0406
Q&A
12:25
THSY0407
Concluding remarks
AUTHOR
SUMMARY
HIGHLIGHTS
CRITICAL ASSESSMENT